Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical investigation for solid cancers. However, the treatment of solid tumors faces more pronounced hurdles, such as increased on-target off-tumor toxicities,...
Main Authors: | Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman, Thorbald van Hall |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/2/287 |
Similar Items
-
Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
by: Mingpeng Fu, et al.
Published: (2019-06-01) -
Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
by: Gabriele Antonarelli, et al.
Published: (2021-08-01) -
Producing and prospects for the use of bispecific antibodies for the treatment of cancer
by: S. E. Sedykh, et al.
Published: (2019-01-01) -
Editorial: Bispecific Antibodies for T-Cell Based Immunotherapy
by: Brian H. Santich, et al.
Published: (2020-12-01) -
A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
by: Aerin Yoon, et al.
Published: (2020-03-01)